Metsera Inc.

The company is a clinical biopharmaceutical firm developing MET-097i as an injectable treatment for obesity in a Phase I/Phase 2 clinical trial involving overweight or obese healthy volunteers. Incorporated in Delaware, the company is focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.

Obesity and overweight are among the fastest-growing and most prevalent chronic human conditions, affecting approximately 2.5 billion people worldwide and contributing to a broad range of severe diseases. Currently approved NuSH analog peptides represent a promising treatment option for these conditions. The company utilizes its proprietary MINT peptide library of NuSH analog peptides, along with its Half-life Augmentation by Lipid Optimization (HALO) half-life extending platform and MOMENTUM oral NuSH analog peptide delivery platform, to develop highly differentiated product candidates. These candidates are being advanced into clinical trials for obesity and overweight treatment.